Showing 4791-4800 of 5623 results for "".
- SimulEYE BIO Shield Launchedhttps://modernod.com/news/simuleye-bio-shield-launched/2478014/SimulEYE Ophthalmic Surgical Training Models has launched the SimulEYE BIO Shield, which is designed to protect eye care professionals and patients. The lightweight shield easily and securely mounts to a wall, using a proprietary magnet system, according to SimulEYE. The shield can be snap
- CorNeat Vision’s Synthetic Cornea Approved for First-in-Human Implantationhttps://modernod.com/news/corneat-visions-synthetic-cornea-approved-for-first-in-human-implantation/2478011/The CorNeat KPro, which says it is developing the first synthetic cornea that bio-integrates with the eye wall, received approval to begin a clinical trial at Beilinson Hospital, Israel. The clinical trial, approved by Israel’s
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Women in Ophthalmology (WIO) 2020 Summer Symposium Goes Virtualhttps://modernod.com/news/women-in-ophthalmology-wio-2020-summer-symposium-goes-virtual/2477999/Due to the recent rise in COVID-19 cases in Florida, Women in Ophthalmology (WIO) has decided to is move its Summer Symposium to an all-virtual platform on August 21-23, 2020. “In classic WIO fashion, we have planned an innovative meeting like no other with 24 hours of CME, scientifi
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- New $1-Billion Fund Aims to Rescue “Collapsing” Antibiotic Pipelinehttps://modernod.com/news/new-1-billion-fund-aims-to-rescue-collapsing-antibiotic-pipeline/2477997/More than 20 biopharmaceutical companies on Thursday joined forces to invest nearly $1 billion in a new fund aimed at supporting the development of antibiotics to address the rapid rise of antimicrobial resistance (AMR). The AMR Action Fund, spearheaded by the International Federation of Ph
- BD Launches 15-minute Coronavirus Antigen Test, Promises Millions in Coming Monthshttps://modernod.com/news/bd-launches-15-minute-coronavirus-antigen-test-promises-millions-in-coming-months/2477994/The FDA granted an emergency authorization to a portable coronavirus antigen test developed by BD, similar to a rapid flu test, designed to allow hospitals, doctors’ offices, urgent care centers, and retail pharmacies to examine a person showing symptoms in about 15 minutes, accor
- LumiThera Closes Series C Round of Financinghttps://modernod.com/news/lumithera-closes-series-c-round-of-financing/2477993/LumiThera announced it has completed its Series C financing. The company raised approximately $14 million to support further commercialization of its Valeda Light Delivery System for the treatment for dry age-related macular degeneration (AMD), to complete its LIGHTS
- Accelmed Partners Completes Acquisition of TearLabhttps://modernod.com/news/accelmed-partners-completes-acquisition-of-tearlab/2477991/Private equity firm Accelmed Partners II (AP-II) completed its $25 million acquisition of dry eye device maker TearLab. As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery platform and seek out targeted acquisition opp